Pfizer's Potential Competition in Obesity Market with Lilly and Novo Nordisk
Saturday, 4 May 2024, 10:45
Murky Outlook
Pfizer's aspirations for its obesity drug danuglipron faced setbacks in early-stage studies, casting doubts on its future prospects.
What About an Acquisition?
Pfizer may consider acquiring biopharmaceutical companies like Viking Therapeutics or Altimmune with promising obesity drug candidates.
However, Pfizer's CFO emphasized the focus on dividend and debt management in the near term.
Weighing In: Pfizer remains optimistic about its potential in the obesity market, signaling its intent to compete with industry leaders.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.